AF
RLAY icon

Amalgamated Financial’s Relay Therapeutics RLAY Stock Holding History

Amalgamated Financial’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$332K Buy
+11,087
New +$269K ﹤0.01% 1690

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Amalgamated Financial's RLAY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Relay Therapeutics (RLAY) in Q1 2022: 11,087 shares worth $332K. The stake represents ﹤0.01% of the portfolio and ranks #1690 among its holdings.

140 funds tracked by Wall St. Rank hold RLAY as of Q1 2022.

  • Amalgamated Financial held 11,087 shares of Relay Therapeutics worth $332K as of Q1 2022.
  • Relay Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Relay Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1690 holding.
  • 140 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.